149 related articles for article (PubMed ID: 27093453)
1. New Robust and Reproducible Stereological IHC Ki67 Breast Cancer Proliferative Assessment to Replace Traditional Biased Labeling Index.
Bigras G; Dong WF; Canil S; Hugh J; Berendt R; Wood G; Yang H
Appl Immunohistochem Mol Morphol; 2017; 25(10):687-695. PubMed ID: 27093453
[TBL] [Abstract][Full Text] [Related]
2. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the Ki67 labeling index: a Japanese validation ring study.
Niikura N; Sakatani T; Arima N; Ohi Y; Honma N; Kanomata N; Yoshida K; Kadoya T; Tamaki K; Kumaki N; Iwamoto T; Sugie T; Moriya T
Breast Cancer; 2016 Jan; 23(1):92-100. PubMed ID: 24794952
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237
[TBL] [Abstract][Full Text] [Related]
5. Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer.
Besusparis J; Plancoulaine B; Rasmusson A; Augulis R; Green AR; Ellis IO; Laurinaviciene A; Herlin P; Laurinavicius A
Diagn Pathol; 2016 Aug; 11(1):82. PubMed ID: 27576949
[TBL] [Abstract][Full Text] [Related]
6. Luminal A versus luminal B breast cancer: MammaTyper mRNA versus immunohistochemical subtyping with an emphasis on standardised Ki67 labelling-based or mitotic activity index-based proliferation assessment.
Finsterbusch K; Decker T; van Diest PJ; Focke CM
Histopathology; 2020 Apr; 76(5):650-660. PubMed ID: 31846096
[TBL] [Abstract][Full Text] [Related]
7. Quantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast cancer.
Sun JZ; Chen C; Jiang G; Tian WQ; Li Y; Sun SR
Int J Nanomedicine; 2014; 9():1339-46. PubMed ID: 24648732
[TBL] [Abstract][Full Text] [Related]
8. Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma.
Laurinavicius A; Plancoulaine B; Rasmusson A; Besusparis J; Augulis R; Meskauskas R; Herlin P; Laurinaviciene A; Abdelhadi Muftah AA; Miligy I; Aleskandarany M; Rakha EA; Green AR; Ellis IO
Virchows Arch; 2016 Apr; 468(4):493-502. PubMed ID: 26818835
[TBL] [Abstract][Full Text] [Related]
9. The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.
Thakur SS; Li H; Chan AMY; Tudor R; Bigras G; Morris D; Enwere EK; Yang H
PLoS One; 2018; 13(1):e0188983. PubMed ID: 29304138
[TBL] [Abstract][Full Text] [Related]
10. Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients.
Chen X; Zhu S; Fei X; Garfield DH; Wu J; Huang O; Li Y; Zhu L; He J; Chen W; Jin X; Shen K
BMC Cancer; 2015 Oct; 15():822. PubMed ID: 26514283
[TBL] [Abstract][Full Text] [Related]
11. Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas.
Ahmed ST; Ahmed AM; Musa DH; Sulayvani FK; Al-Khyatt M; Pity IS
Asian Pac J Cancer Prev; 2018 Apr; 19(4):955-959. PubMed ID: 29693354
[TBL] [Abstract][Full Text] [Related]
12. Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.
Elkablawy MA; Albasri AM; Mohammed RA; Hussainy AS; Nouh MM; Alhujaily AS
Saudi Med J; 2016 Feb; 37(2):137-41. PubMed ID: 26837394
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis.
Gándara-Cortes M; Vázquez-Boquete Á; Fernández-Rodríguez B; Viaño P; Ínsua D; Seoane-Seoane A; Gude F; Gallego R; Fraga M; Antúnez JR; Curiel T; Pérez-López E; García-Caballero T
Virchows Arch; 2018 Feb; 472(2):195-203. PubMed ID: 28825136
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
15. An interobserver reproducibility analysis of size-set semiautomatic counting for Ki67 assessment in breast cancer.
Wang YX; Wang YY; Yang CG; Bu H; Yang WT; Wang L; Xu WM; Zhao XL; Zhao WX; Li L; Song SL; Yang JL
Breast; 2020 Feb; 49():225-232. PubMed ID: 31911370
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers.
Yagi T; Inoue N; Yanai A; Murase K; Imamura M; Miyagawa Y; Enomoto Y; Nishimukai A; Takatsuka Y; Hirota S; Akazawa K; Miyoshi Y
Breast Cancer; 2016 Mar; 23(2):224-30. PubMed ID: 25082658
[TBL] [Abstract][Full Text] [Related]
17. St Gallen 2015 subtyping of luminal breast cancers: impact of different Ki67-based proliferation assessment methods.
Focke CM; van Diest PJ; Decker T
Breast Cancer Res Treat; 2016 Sep; 159(2):257-63. PubMed ID: 27558625
[TBL] [Abstract][Full Text] [Related]
18. Impact of Primary Antibody Clone, Format, and Stainer Platform on Ki67 Proliferation Indices in Breast Carcinomas.
Røge R; Nielsen S; Riber-Hansen R; Vyberg M
Appl Immunohistochem Mol Morphol; 2019; 27(10):732-739. PubMed ID: 31460869
[TBL] [Abstract][Full Text] [Related]
19. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
